Latest Information Update: 18 Apr 2002
At a glance
- Originator MediGene Inc
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 18 Apr 2002 Discontinued - Preclinical for Cancer in Canada (unspecified route)
- 13 Jun 2001 No-Development-Reported for Cancer in Canada (Unknown route)
- 26 Jan 2001 NeuroVir Therapeutics has been acquired by MediGene AG and is now called MediGene Inc